SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
CONTACT: Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189
CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family…
Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL /…
LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force…
Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a…
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that…
SOMERVILLE, NJ / ACCESSWIRE / April 3, 2024 / LPW Training Services, a global industry…